The generics maker says it may take five years for its iteration of the GSK asthma/COPD brand to hit the market.
The experimental LAMA/LABA combination could shake up the category.
Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M
The FDA approved the Breo/Ellipta combo, but analysts are wary about its potential to go beyond the COPD indication in the US.
Health-seeking consumers continue social-media push; Scioderm scores FDA's "Breakthrough" designation for bullosa agent; and GSK files NDA for airway treatment.
An FDA advisory committee recommended approving Breo for COPD. Assuming it goes through, GSK will have to woo payers to upgrade from the older drug.
Boehringer Ingelheim is partnering with the Country Music Association for a Tune Up For COPD Songwriting Competition featuring country music stars Billy Ray Cyrus and Patty Loveless.
AstraZeneca is rolling out an unbranded COPD education campaign featuring comedian and actor Robert Klein. The campaign, dubbed Rethink COPD, is aimed at getting sufferers to consider their options with respect to diet, exercise and, of course, medication.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.